Vizora日本語

JCR PharmaceuticalsJCR Pharmaceuticals Co.,Ltd.4552東証プライム医薬品FY ending Mar 2026, consolidated, J-GAAP

JCR Pharmaceuticals revenue and profit

Out of every ¥100 of sales, about ¥1 is left as operating profit. Revenue changed +21.9% from the prior year, and it swung back to an operating profit.

Five-year trend

Revenue¥40.3B
FY ending Mar 2022: ¥51.1B¥51.1BFY ending Mar 2023: ¥34.3B¥34.3BFY ending Mar 2024: ¥42.9B¥42.9BFY ending Mar 2025: ¥33.1B¥33.1BFY ending Mar 2026: ¥40.3B¥40.3BFY22FY23FY24FY25FY26
Operating income¥555M
FY ending Mar 2022: ¥19.9B¥19.9BFY ending Mar 2023: ¥4.97B¥4.97BFY ending Mar 2024: ¥7.53B¥7.53BFY ending Mar 2025: -¥6.22B-¥6.22BFY ending Mar 2026: ¥555M¥555MFY22FY23FY24FY25FY26
Operating margin1.4%
FY ending Mar 2022: 39.0%39.0%FY ending Mar 2023: 14.5%14.5%FY ending Mar 2024: 17.6%17.6%FY ending Mar 2025: -18.8%-18.8%FY ending Mar 2026: 1.4%1.4%FY22FY23FY24FY25FY26

What drives ROE

Net margin × asset turnover = ROA; ROA × financial leverage = ROE

Net margin5.4%
Asset turnover0.38×
ROA2.0%
ROA2.0%
Financial leverage2.34×
ROE4.8%

Denominators: average assets and average equity. Derived from reported values; ROE is shown only for positive profit and equity.

Net margin5.4%
2022: 28.4%28.4%2023: 11.0%11.0%2024: 12.8%12.8%2026: 5.4%5.4%2223242526
Asset turnover0.38×
2022: 0.53×0.53×2023: 0.36×0.36×2024: 0.43×0.43×2026: 0.38×0.38×2223242526
ROA2.0%
2022: 14.9%14.9%2023: 3.9%3.9%2024: 5.6%5.6%2025: -4.3%-4.3%2026: 2.0%2.0%2223242526
Financial leverage2.34×
2022: 1.95×1.95×2023: 1.91×1.91×2024: 1.89×1.89×2026: 2.34×2.34×2223242526
ROE4.8%
2022: 29.2%29.2%2023: 7.5%7.5%2024: 10.5%10.5%2026: 4.8%4.8%2223242526
PeriodNet marginAsset turnoverROAFinancial leverageROE
202228.4%0.53×14.9%1.95×29.2%
202311.0%0.36×3.9%1.91×7.5%
202412.8%0.43×5.6%1.89×10.5%
2025——×-4.3%—×—
20265.4%0.38×2.0%2.34×4.8%

Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.

Asset intensity and goodwill

Annual trends in tangible-asset ratios and goodwill balance.

PPE ÷ revenue97.3%
2021: 57.1%57.1%2022: 52.4%52.4%2023: 95.2%95.2%2024: 70.1%70.1%2025: 112.2%112.2%2026: 97.3%97.3%212223242526
PPE ÷ total assets35.9%
2021: 23.3%23.3%2022: 27.6%27.6%2023: 34.4%34.4%2024: 29.4%29.4%2025: 35.4%35.4%2026: 35.9%35.9%212223242526

Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition

Investment and working-capital efficiency

Track R&D investment and how long operating capital remains tied up before sales turn into cash.

R&D spending¥16.8B
2021: ¥5.36B¥5.36B2022: ¥7.17B¥7.17B2023: ¥8.8B¥8.8B2024: ¥11.2B¥11.2B2025: ¥15.4B¥15.4B2026: ¥16.8B¥16.8B212223242526
R&D / revenue41.6%
2021: 17.8%17.8%2022: 14.0%14.0%2023: 25.6%25.6%2024: 26.2%26.2%2025: 46.7%46.7%2026: 41.6%41.6%212223242526
Receivable days—
2021: 99d99d212223242526
Payable days—
2021: 137d137d2022: 46d46d212223242526

R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.

Income statement (JPY millions)

ItemFY ending Mar 2022FY ending Mar 2023FY ending Mar 2024FY ending Mar 2025FY ending Mar 2026
Revenue51,08234,34342,87133,07240,319
Cost of revenue10,4618,88611,62010,90210,134
Gross profit40,62025,45631,25122,16930,185
SG&A20,68620,48023,71928,38929,629
Operating income19,9334,9757,531-6,219555
Pretax income19,4045,4127,244-5,9833,224
Income tax4,8861,6251,707-1,5861,017
Net income attributable to owners14,5073,7725,507-4,4602,178
Operating margin39.0%14.5%17.6%-18.8%1.4%

Balance sheet (reported items)

Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.

Assets

Cash 13%
Property, plant and equipment 36%
2%
7%
Other assets 42%

Funding

Other liabilities 57%
Equity 43%

Each bar totals 100% of assets; other is the residual.

ItemFY ending Mar 2022FY ending Mar 2023FY ending Mar 2024FY ending Mar 2025FY ending Mar 2026
Cash and equivalents¥30.7B¥13.3B¥18.8B¥13.2B¥14B
Total assets¥97.1B¥94.9B¥102.2B¥104.8B¥109.2B
Net assets¥51.1B¥52.4B¥56.5B¥47.7B¥47.4B
Share capital¥9.06B¥9.06B¥9.06B¥9.06B¥9.06B
Property, plant and equipment¥26.8B¥32.7B¥30B¥37.1B¥39.2B
Intangible assets excluding goodwill¥2.96B¥3.65B¥3.5B¥2.96B¥2.6B
Investment securities¥2.23B¥8.87B¥9.12B¥9.63B¥7.83B
Current assets¥62.2B¥47.8B¥57.6B¥51.5B¥56.1B
Current liabilities¥42.1B¥35.8B¥30.1B¥43.7B¥48.1B
Trade payables¥1.32B————
Short-term borrowings¥15.2B¥16.8B¥8.2B¥23B¥38.1B
Long-term borrowings¥2.45B¥5.5B¥14.3B¥12.1B¥12.2B
Bonds¥500M————
Interest-bearing debt¥18.1Bderived————
Total liabilities¥46B¥42.5B¥45.8B¥57.1B¥61.9B
Non-controlling interests¥205M¥251M¥297M¥392M¥417M
Equity attributable to owners of parent¥49.7B¥50.7B¥53.8B¥45.9B¥45.7B
Retained earnings¥33.2B¥34.3B¥37.3B¥31.5B¥31.2B
Treasury stock-¥3.6B-¥2.98B-¥2.96B-¥5.07B-¥4.97B

Sources

Show source documents (6)

  • EDINET (FSA Japan)

    訂正有価証券報告書－第51期(2025/04/01－2026/03/31)

    ID S100YSOS2026-07-29Open

  • EDINET (FSA Japan)

    有価証券報告書－第50期(2024/04/01－2025/03/31)

    ID S100W3Q52025-06-25Open

  • EDINET (FSA Japan)

    有価証券報告書－第49期(2023/04/01－2024/03/31)

    ID S100TQM62024-06-26Open

  • EDINET (FSA Japan)

    訂正有価証券報告書－第48期(2022/04/01－2023/03/31)

    ID S100SNAG2024-01-19Open

  • EDINET (FSA Japan)

    有価証券報告書－第47期(令和3年4月1日－令和4年3月31日)

    ID S100OAJT2022-06-22Open

  • EDINET (FSA Japan)

    有価証券報告書－第46期(令和2年4月1日－令和3年3月31日)

    ID S100LL7F2021-06-23Open

Extracted from XBRL: 52 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open MarkdownShare on XSave image